Dataset Information

High preoperative albumin-bilirubin score predicts poor survival in patients with newly diagnosed high-grade gliomas.

ABSTRACT:

Objective

To determine the prognostic value of the preoperative Albumin-bilirubin (ALBI) score in high-grade glioma (HGG) patients.

Methods

A retrospective study of 194 HGG patients was conducted. ROC analysis was used to determine the optimal cut-off value of ALBI score. Univariate and multivariate analysis was performed to identify prognostic factors associated with progression free survival (PFS) and overall survival (OS). The resulting prognostic models were externally validated by a demographic-matched cohort of 130 HGG patients.

Results

Optimal cutoff value of ALBI score was -2.941. In training set, ALBI was correlated with age (P?=?0.001), tumor location (P?=?0.012) and adjuvant therapy (P?=?0.016). Both PFS (8.27?vs. 18.40 months, P<0.001) and OS (13.93?vs. 27.57 months, P<0.001) were significantly worse in the ALBI-high group. Strikingly, patients in ALBI-low group had 56% decrease in the risk of tumor progression and 57% decrease in the risk of death relative to high ALBI. Multivariate analysis further identified ALBI score as an independent predictor for both PFS (HR=0.47, 95% CI 0.34, 0.66) and OS (HR=0.45, 95% CI 0.32, 0.63). The ALBI score remained independent prognostic value in the validation set for both PFS (P?=?0.01) and OS (P?=?0.007). Patients with low ALBI score had better PFS and OS in all subgroups by tumor grade and treatment modalities.

Conclusions

The preoperative ALBI score is a noninvasive and valuable prognostic marker for HGG patients.

SUBMITTER: Zhang J

PROVIDER: S-EPMC7893483 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

High preoperative albumin-bilirubin score predicts poor survival in patients with newly diagnosed high-grade gliomas.

Zhang Jie J Xu Qiuyan Q Zhang Hua H Zhang Yihong Y Yang Yu Y Luo Huidan H Lin Xiaoyan X He Xingqin X Mou Yonggao Y Zhou Zhihuan Z He Zhenqiang Z

Translational oncology 20210214 4

<h4>Objective</h4>To determine the prognostic value of the preoperative Albumin-bilirubin (ALBI) score in high-grade glioma (HGG) patients.<h4>Methods</h4>A retrospective study of 194 HGG patients was conducted. ROC analysis was used to determine the optimal cut-off value of ALBI score. Univariate and multivariate analysis was performed to identify prognostic factors associated with progression free survival (PFS) and overall survival (OS). The resulting prognostic models were externally validat ...[more]

PMID: 33596518

Similar Datasets

Project description:BackgroundThe radiation dose for patients with low-grade gliomas (LGGs) is controversial. The objective of this study was to investigate the impact of the radiation dose on survival for patients with LGGs and especially for molecularly defined subgroups.MethodsThree hundred fifty-one patients with newly diagnosed LGGs from the multicenter Chinese Glioma Cooperative Group received postoperative radiotherapy (RT) in 2005-2018. The RT dose, as a continuous variable, was entered into a Cox regression model using penalized spline regression to allow for a nonlinear relationship between the RT dose and overall survival (OS) or progression-free survival (PFS). Inverse probability of treatment weighting (IPTW)-adjusted propensity scores were used to correct for potential confounders. Dose effects on survival within IDH mutation and 1p/19q codeletion defined subgroups were analyzed.ResultsThe risk of mortality and disease progression decreased sharply until 54 Gy. High-dose RT (≥54 Gy) was associated with significantly better 5-year OS (81.7% vs 64.0%; hazard ratio [HR], 0.33; P < .001) and PFS (77.4% vs 54.5%; HR, 0.46; P < .001) than low-dose RT (<54 Gy). IPTW correction confirmed the associations (HR for OS, 0.44; P = .001; HR for PFS, 0.48; P = .003). High-dose RT was associated with longer PFS (HR, 0.25; P = .002; HR, 0.21; P = .039) and OS (HR, 0.27; P = .006; HR, 0.07; P = .017) in IDH-mutant/1p/19q noncodeleted and IDH wild-type subgroups, respectively. No significant difference in survival was observed with high-dose RT in the IDH-mutant/1p/19q codeleted subgroup.ConclusionsHigh-dose RT (≥54 Gy) was effective in LGGs. Patients with an IDH mutation/1p/19q noncodeletion or IDH wild-type may need to be considered for high-dose RT.Lay summaryThe radiotherapy dose-response was observed in patients with low-grade gliomas, and high-dose radiotherapy (≥54 Gy) was associated with improved survival. Patients with an IDH mutation/1p/19q noncodeletion or wild-type IDH may have improved survival with the administration of high-dose radiotherapy.

Dataset Information

High preoperative albumin-bilirubin score predicts poor survival in patients with newly diagnosed high-grade gliomas.

Objective

Methods

Results

Conclusions

Publications

High preoperative albumin-bilirubin score predicts poor survival in patients with newly diagnosed high-grade gliomas.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure